Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24040221 | 1.00 | SPHK1 (0.38) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL19619621 | 1.00 | SPHK1 (0.38) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL20781650 | 0.92 | SPHK1 (0.34) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL20781658 | 0.92 | SPHK1 (0.34) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL23844606 | 0.92 | SPHK1 (0.34) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL21440024 | 0.84 | GPR84 (0.34) | SPHK1FDPS | |
| SCHEMBL20215967 | 0.82 | ADH1C (0.33) | SPHK1BCHEADH1CADH1AADH4 | |
| SCHEMBL23219730 | 0.82 | BCHE (0.37) | SPHK1BCHE | |
| SCHEMBL23733462 | 0.80 | GNAI3 (0.38) | GNAI3GNAO1GNAI1FDPS | |
| SCHEMBL19055353 | 0.80 | SIGMAR1 (0.35) | GNAI3GNAO1GNAI1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | CELON PHARMA S.A. (PL) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111939-A1 | 7-(MORPHOLIN-4-YL)PYRAZOLE[1,5-A]PYRIMIDINE DERIVATIVES WHICH ARE USEFUL FOR THE TREATMENT OF IMMUNE OR INFALMMATORY DISEASES OR CANCER | AFF2, INF2, AFF1 | SPHK1 975/4885BCHE 3782/4885ADH1C 331/4885 |
| US-11180474-B2 | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors | TLR9, TLR7, TLR8 | SPHK1 782/4885BCHE 4783/4885ADH1C 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.